Thursday 8 September 2022 11:04 PM Anti-wrinkle injection that lasts two months longer than Botox approved by FDA trends now
View
comments
An injectable anti-wrinkle treatment that lasts about two months longer than Botox has been given the green light for use in adults by the Food and Drug Administration (FDA) — becoming the first of its type to receive approval in over a decade.
Daxxify — manufactured by Revance — is injected into worry lines on the face and around the eyes. It lasts for about six months, outpacing the three to four months for its main competitor Botox.
Mark Foley, CEO of the Tennessee-based biotechnology firm, said it is already investigating whether it could also be used to treat lip spasms and cervical dystonia — when neck muscles contract involuntarily. Daxxify was stumbled on during research into a cream that could slow wrinkles.
More and more Americans are signing up for injections to slow aging every year — with the current market valued at $3.2 billion. But scientists warn over side effects including drooping eyelids, muscle weakness and trouble swallowing.
Pictured above are vials of the drug Daxxify, manufactured by a company in Nashville, Tennessee. It has been approved for use by the Food and Drug Administration
Daxxify works in the same way to Botox, a neuromuscular blocking agent which effectively freezes muscles — helping to prevent wrinkles.
Its developers hope to encourage more people to switch to the
